Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Acrux Limited

Market Cap 8.73M 6.15M 5.32M 4.9M 4.58M 8.59M 585M 57.84M 22.55M 285M 23.1M 22.61M 986M P/E Ratio 2024
-3.44x
P/E Ratio 2025 -0.95x
Enterprise Value 11.5M 8.11M 7M 6.45M 6.04M 11.32M 771M 76.21M 29.71M 375M 30.43M 29.79M 1.3B EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 day-5.56%
1 week+41.67%
Current month+41.67%
1 month+41.67%
3 months+41.67%
6 months+6.25%
Current year+13.33%
1 week 0.01
Extreme 0.012
0.02
1 month 0.01
Extreme 0.009
0.02
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.16
10 years 0.01
Extreme 0.009
0.84
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 15/02/2015
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
-5.56%+41.67%-26.09%-65.31% 6.46M
+0.75%+1.55%+6.93%+83.72% 44.96B
-0.20%-5.34%+38.85%+88.89% 33.53B
+0.44%-0.66%-8.69%+43.35% 11.67B
-0.11%+1.85%+12.86%+117.57% 11.62B
+0.49%+0.78%+37.07%+126.43% 8.97B
+2.40%+0.08%+17.77%+43.22% 6.89B
-1.12%+0.77%+40.21%-17.13% 6.55B
+1.37%-0.31%+32.92%+241.77% 6.32B
+0.51%-2.46%-39.66%-6.34% 5.12B
Average -0.13%+4.58%+11.22%+65.62% 13.56B
Weighted average by Cap. +0.40%-0.96%+17.58%+84.28%

Financials

2024 2025
Net sales 5.09M 3.59M 3.1M 2.86M 2.68M 5.01M 341M 33.75M 13.16M 166M 13.48M 13.19M 575M 1.19M 839K 725K 668K 625K 1.17M 79.78M 7.89M 3.08M 38.83M 3.15M 3.08M 134M
Net income -5.8M -4.09M -3.53M -3.26M -3.05M -5.71M -389M -38.44M -14.99M -189M -15.35M -15.03M -655M -5.94M -4.19M -3.62M -3.34M -3.12M -5.85M -399M -39.41M -15.36M -194M -15.74M -15.4M -672M
Net Debt 759K 535K 462K 426K 399K 747K 50.88M 5.03M 1.96M 24.77M 2.01M 1.97M 85.76M 2.77M 1.96M 1.69M 1.56M 1.46M 2.73M 186M 18.37M 7.16M 90.45M 7.34M 7.18M 313M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
12/06/26 0.0170 $ -5.56% 2,127,316
11/06/26 0.0180 $ +12.50% 3,458,763
10/06/26 0.0160 $ +33.33% 5,602,843
09/06/26 0.0120 $ 0.00% 719,941
05/06/26 0.0120 $ 0.00% 708,933

Annual profits - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!